Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=52 Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma
Asthma
Primary: Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 15 Minutes (AUC0-15 Min) Post-dose — 2.969; 2.970; 2.955…
N/A N=20 Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide
Asthma
Primary: Airway Blood Flow (Qaw) — 22.3; 29.4; 34.1; 28.2 percentage of change from baseline
Phase 4 N=20 Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
COPD
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 1 Week — 0.069; 0.010; 0.121; 0.023 Liters
N/A N=1,283 Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants
N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Phase 3 N=51 Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270)
Asthma, Exercise-Induced
Primary: Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Postdose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)…
Phase 2 N=15 PF-04191834 Single Dose Bronchodilatory Study In Asthma.
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) — 2.624; 2.626; 2.585; 2.579 L
N/A N=51 The Effects of Broccoli Sprout Extract on Obstructive Lung Disease
Asthma · COPD
Primary: The Primary Outcome is the Change in Bronchodilation and Bronchoprotection After Broccoli Sprout Extract — 10.3; 26.7 index
Phase 3 N=62 Montelukast in Exercise-Induced Bronchospasm - 2004 (0476-275)
Asthma, Exercise-Induced
Primary: Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Post-dose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)…
N/A N=284 Bronchial Thermoplasty in Severe Persistent Asthma
Severe Asthma
Primary: Subjects Experiencing Severe Exacerbations (Rates) — 132; 118; 118; 106 Participants
N/A N=25 Neurostimulation for the Relief of Acute Bronchoconstriction
Asthma
Primary: Safety- Number of Participants With Adverse Events — 16 Participants
Phase 3 N=15 The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia
Familial Dysautonomia
Primary: Change From Baseline of Forced Vital Capacity — 5.5; 4.7; 0.9 percentage change from baseline
Phase 2 N=14 Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma
Asthma
Primary: Measurement of Change in Methacholine PC20 From Baseline Compared With Placebo 24 Hours After Dosing — 1.48; -0.2 mg/mL
Phase 3 N=38 Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)
Exercise-Induced Bronchoconstriction (EIB)
Primary: Maximum Percentage Fall From Baseline in Forced Expiratory Volume in 1 Second (FEV1) up to 60 Minutes After the Exercise Challenge — 6.21; 22.38 percentage change from…
Phase 2 N=31 Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma
Asthma
Primary: Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 24 Hours — 0.793; 1.950; 2.504; 3.236 Log base 2…
Phase 2 N=48 Effect of BIBW 2948 BS in COPD
Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic
Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305
N/A N=18 Airway Smooth Muscle and Asthma Severity
Asthma
Primary: Difference in ASM Mass Between Groups
N/A N=10 Clinical Evidence of pH Dependent ß2 Adrenergic Transport Mechanisms in the Airway
Healthy Volunteers
Primary: Changes in Airway Blood Flow After 180μg Albuterol by Inhalation (ΔQaw) vs Baseline — 16.8; 14.5; -0.2; 2.0 changes from baseline in μl.min-1.ml-1
Phase 3 N=148 Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
Asthma
Primary: Trough FEV1 After One Week of Treatment, Point Estimate — 2.392; 2.392; 2.303 Liters — p=<0.001
Phase 3 N=60 Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Asthma
Primary: Provocative Concentration of Methacholine Which Produces a 20% Fall in FEV1 (PC20) — 17.70; 9.88; 20.10; 10.78 mg/mL — p=<0.001
N/A N=38 Effects of Inspiratory Muscle Training in Patients With Bronchiectasis
Bronchiectasis
Primary: Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP) at 8 Weeks — 60; 71; 84; 69 cmH2O — p=0.005
Phase 4 N=25 Single Dose Bronchodilatory Study in Asthma
Asthma
Primary: Change From Baseline in FEV1 — 2.84 Liter
N/A N=51 Effects of Whole Sprouts on Airway Allergic Inflammation
Allergic Rhinitis · Asthma · Allergy
Primary: Exhaled Nitric Oxide Concentrations — 22; 19 ppb
Phase 4 N=20 Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes
Bronchospasm, Exercise-Induced
Primary: Spirometry and Specific Airway Conductance Measured by Body Plethysmography Before and After Exercise Challenge After Randomized Administration of Either Inhaled…
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
N/A N=126 The Natural History of Small Airways Physiology in Diseased and Healthy States
Asthma · COPD · Interstitial Lung Disease
Primary: FEV1 — 3.03; 2.32; 3.18; 2.76 L
Phase 3 N=18 Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
Chronic Obstructive Pulmonary Diseases · Chronic Airways Limitation · Bronchitis
Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage
Phase 4 N=36 Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation
Chronic Obstructive Pulmonary Disease · COPD
Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85
Phase 3 N=47 Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)
Asthma, Exercise-Induced
Primary: Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Post-dose in Patients With Exercise-Induced Bronchoconstriction…